Artesunate enhances the immune response of rabies vaccine as an adjuvant

Luo, Jun; Zhang, Yue; He, Hongling; Liu, Qing; Huang, Shile; Guo, Xingchen

doi:10.1016/j.vaccine.2019.09.077

Cited by 5 publications

(3 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Recent research has demonstrated the broad antiviral potency of ART [ 75 ]. These viruses include herpes, human cytomegalovirus (HCMV) [ 10 ], rabies [ 76 ], etc. ART has been shown to have some anti-fibrosis efficacy [ 77 ] and can inhibit dermatitis due to its anti-inflammatory properties [ 78 ].…”

Section: Malaria and Its Parasite Life Cyclementioning

confidence: 99%

“…Immunizing mice with inactivated CVS-11 (rabies strain) + ART caused higher virus-neutralized antibody (VNA) level in the peripheral blood, and ART significantly enhanced VNA induction in mice immunized with inactivated rabies strain rHEP-dG. Since mice treated with rHEP-dG + ART had a higher survival rate compared with those treated with rHEP-dG + PBS, it showed that ART can enhance the protective effect of the rabies vaccine [ 76 ].…”

Section: Malaria and Its Parasite Life Cyclementioning

confidence: 99%

See 1 more Smart Citation

Recent Advances in the Therapeutic Efficacy of Artesunate

2022

View full text Add to dashboard Cite

Artesunate, a semisynthetic artemisinin derivative, is well-known and used as the first-line drug for treating malaria. Apart from treating malaria, artesunate has also been found to have biological activity against a variety of cancers and viruses. It also exhibits antidiabetic, anti-inflammatory, anti-atherosclerosis, immunosuppressive activities, etc. During its administration, artesunate can be loaded in liposomes, alone or in combination with other therapeutic agents. Administration routes include intragastrical, intravenous, oral, and parenteral. The biological activity of artesunate is based on its ability to regulate some biological pathways. This manuscript reports a critical review of the recent advances in the therapeutic efficacy of artesunate.

show abstract

Section: Malaria and Its Parasite Life Cyclementioning

confidence: 99%

Section: Malaria and Its Parasite Life Cyclementioning

confidence: 99%

Recent Advances in the Therapeutic Efficacy of Artesunate

2022

View full text Add to dashboard Cite

show abstract

“…Rabies is one of the oldest worldwide infectious diseases with highest mortality rate of all known diseases which cause roughly 59,000 deaths every year according to the World Health Organization [ [1] , [2] , [3] ]. This fatal disease is caused by the rabies virus (RABV), a non-segmented negative-strand RNA virus from the Rhabdoviridae family, Mononegavirales order, Lyssavirus genus, is responsible for this lethal illness [ [4] , [5] , [6] ].…”

Section: Introductionmentioning

confidence: 99%

Adjuvant activity of cordycepin, a natural derivative of adenosine from Cordyceps militaris, on an inactivated rabies vaccine in an animal model

Chen,

Liao,

Ren

et al. 2024

Heliyon

View full text Add to dashboard Cite

Artesunate and Dihydroartemisinin Inhibit Rabies Virus Replication

et al. 2021

Self Cite

View full text Add to dashboard Cite

Rabies is caused by infection of rabies virus (RABV) and remains a serious threat to the global public health. Except for the requirement for cold chain and high cost of human rabies immune globulin, no small molecule drugs are currently available for clinical treatment of rabies. So, it is of great importance to identify novel compounds that can effectively inhibit RABV infection. Artesunate (ART) and dihydroartemisinin (DHA), two derivatives of artemisinin, are widely used for treatment of malaria in adults and children, showing high safety. In this study, we found that both ART and DHA were able to inhibit RABV replication in host cells at a low concentration (0.1 μmol/L). The antiviral effects of ART and DHA were independent of viral strains and cell lines. Pre-treatment with ART or DHA for 2 h in vitro did not affect the viral replication in host cells, implying that ART and DHA neither reduced the viability of RABV directly nor inhibited the binding and entrance of the virus to host cells. Further studies revealed that ART and DHA inhibited RABV genomic RNA synthesis and viral gene transcription. Treatment with ART or DHA (5 mg/kg) by intramuscular injection improved, to some extent, the survival rate of RABV-challenged mice. Combination treatment with derivatives of artemisinin and mannitol significantly improved the survival rate of RABV-challenged mice. The results suggest that ART and DHA have a great potential to be explored as new anti-rabies agents for treatment of rabies.

show abstract

Artesunate enhances the immune response of rabies vaccine as an adjuvant

Cited by 5 publications

References 23 publications

Recent Advances in the Therapeutic Efficacy of Artesunate

Recent Advances in the Therapeutic Efficacy of Artesunate

Adjuvant activity of cordycepin, a natural derivative of adenosine from Cordyceps militaris, on an inactivated rabies vaccine in an animal model

Artesunate and Dihydroartemisinin Inhibit Rabies Virus Replication

Contact Info

Product

Resources

About